Ovarian cancer has the highest mortality among gynecological cancers. Although ovarian cancer usually responds well to chemotherapy, most patients still have a poor prognosis. EIF2B5 is a crucial molecule in posttranscriptional modifications involved in tumor progression, and here we investigated the prognostic role of EIF2B5 in ovarian cancer. We examined the differential expression of EIF2B5 mRNA in ovarian cancer by exploring The Cancer Genome Atlas (TCGA) database. The chi square test was used to identify a clinical correlation. Survival analysis and Cox regression model were performed to determine the association between EIF2B5 expression and overall survival (OS) in ovarian cancer patients. As a result, Low EIF2B5 expression was found in ovarian cancer tissues and correlated with survival status. Survival analysis showed that ovarian cancer patients with low EIF2B5 expression had a short OS. Moreover, Cox regression analysis indicated that low EIF2B5 expression was an independent risk factor for a poor prognosis in ovarian cancer. Additionally, according to gene set enrichment analysis, mesenchymal transition, angiogenesis, coagulation, and bile acid metabolism were differentially enriched in ovarian cancer with high EIF2B5 expression. In conclusion, Low EIF2B5 expression is an independent risk factor for a poor prognosis in ovarian cancer patients.
Introduction
Ovarian cancer is the most lethal gynecological cancer globally, [1, 2] and despite rapid advancements in treatment methods, the prognosis of ovarian cancer patients remains poor, with few effective prognostic biomarkers available at present. [3] [4] [5] Therefore, there is an urgent need for new molecular markers that can be used to predict the prognosis of ovarian cancer patients for the purpose of guiding treatment planning.
As a crucial molecule in posttranscriptional modifications, eukaryotic translation initiation factor 2B subunit 5 (EIF2B5) is important in cancer progression. [6] Early research regarding EIF2B5 mainly aimed to study the roles of its expression in multiple sclerosis, [7, 8] ovarioleukodystrophy, [9] and vanishing white matter (VWM) syndrome. [10] [11] [12] Additionally, recent studies indicated that high EIF2B5 expressed in few cancerous tissue (lung cancer, [13] breast cancer, [14] and liver cancer [15] ) and serve as a prognostic biomarker in hepatocellular carcinoma. [15] Nonetheless, the role of EIF2B5 expression in ovarian cancer remains unclear.
To evaluate the clinical significance of EIF2B5 expression in the prognosis of ovarian cancer patients, we analyzed the prognostic value of EIF2B5 mRNA expression in The Cancer Genome Atlas (TCGA) cohort of ovarian cancer patients. First, we analyzed the differential expression of EIF2B5 in ovarian cancer patients and then studied its correlation with overall survival (OS) among the patients. are shown in boxplots drawn using the ggplot2 package. [17] To determine the high and low EIF2B5 expression groups, and the optimal cutoff value was obtained from ROC curve. Possible clinical correlations between EIF2B5 expression and the clinical characteristics of ovarian cancer patients were evaluated by the chi square test. The survival curves were drawn using Survival Package. [18] The log-rank test was applied to examine the survival difference. Univariate Cox analysis was performed to select relevant variables, and a multivariate Cox model was used to evaluate the independent prognostic role of EIF2B5 expression separate from other clinical characteristics.
GSEA
Gene set enrichment analysis (GSEA) uses predefined gene sets to rank target genes according to the degree of differential expression between the two types of samples, and then to test whether the pre-defined gene sets are at the top or bottom of the sorting table. [19] In the present study, we used GSEA 3.0 software to analyze the data of ovarian cancer patients. We obtained standardized enrichment fractions (NESs) by using permutation analysis 1000 times.
Ethical approval
Ethics committee approval was not necessary because all clinical data used in this study were obtained from a public database and are available for research.
Results

Differential expression of EIF2B5 in ovarian cancer
The data for EIF2B5 expression and clinical features including age, subdivision of cancer, cancer stage, longest dimension, lymphatic invasion, histologic grade, occurrence type, sample type, vital status, and EIF2B5 expression are presented in Table 1 and Figure 1A . From the prepared boxplots, EIF2B5 expression was low in ovarian cancer tissues compared with that observed in normal ovarian tissues. Additionally, low EIF2B5 expression was observed in deceased patients, suggesting a potential connection between the survival status and EIF2B5 expression ( Fig. 1 and Table 2 ).
Correlation of EIF2B5 expression and survival
To explore possible correlations of EIF2B5 expression with clinical factors, we completed the chi square test and found a specific correlation between vital status and expression of EIF2B5 (Table 2) . Moreover, patients with shorter OS time had much lower expression of EIF2B5 ( Fig. 2 , P = .034), which is consistent with results of subgroup analysis, especially among the elderly patients ( Fig. 2 , P = .022).
The univariate Cox model revealed several potential survivalrelated variables including age, occurrence type, and EIF2B5 expression. The Multivariate Cox model suggested that low EIF2B5 expression was an independent risk factor for a poor prognosis in ovarian cancer patients, based on its association with a shorter OS (hazard ratio [HR] = 1.82, P = .008, Table 3 ).
As shown in Table 4 , GSEA revealed significant differences in the enrichment of the MSigDB Collection (NOM P < .05, false discovery rate [FDR] < 0.25). We chose the most essential signaling pathways based on NES (Table 4 ; Fig. 3 ). Figure 3 shows that mesenchymal transition, angiogenesis, coagulation, and bile acid metabolism were enriched in low EIF2B5 expression phenotype, respectively.
Discussion
Although many advances in treatment strategies for ovarian cancer have been explored, the OS of these patients has not been improved. Thus, novel biomarkers that can be used to predict the prognosis of these patients remain urgently needed. [20] [21] [22] [23] [24] [25] [26] According to the results of the present study, low EIF2B5 expression is an independent risk factor for a poor prognosis among ovarian cancer patients. Early studies of EIF2B5 mainly focused on its role in VWM diseases, which involve downregulation of EIF2B5. [8, 10, 11] Recently, several studies began investigating the role of EIF2B5 in various cancers, including lung cancer, [13] breast cancer, [14] and liver cancer. [15] In these studies, EIF2B5 was shown to be overexpressed at both mRNA and protein levels in the cancerous tissues. In contrast, in the present study we observed the opposite phenomenon in which EIF2B5 expression was lower in ovarian Figure 1 . Differential EIF2B5 expression in ovarian cancer. The EIF2B5 expression in all ovarian cancer cases and different groups according to histologic grade, occurrence type, subdivision, lymphatic invasion, patient age, stage, and vital status. cancer tissues than in normal ovarian tissues. This discrepancy may be due to differences in the cancer types, which might suggest exclusive functions and mechanisms of EIF2B5 in ovarian cancer. Moreover, EIF2B5 expression showed a decreasing trend from stage I to stage IV ovarian cancer, suggesting that the function of EIF2B5 may change throughout different stages of ovarian cancer. To better understand the dynamics of EIF2B5 expression in ovarian cancer, a subgroup analysis is necessary. Additionally, considering that the low EIF2B5 expression continued to decline with disease progression, the relationship between EIF2B5 and survival needs to be further studied. Previous research also linked EIF2B5 expression with cancer patients' prognosis. A previous study demonstrated that high EIF2B5 expression is associated with a shorter survival time in colorectal cancer cases. [27] Also, expression of minor alleles of EIF2B5 was found to improve the prognosis of ovarian cancer patients via the inhibition of angiogenesis and tumor growth. [28] However, the association between EIF2B5 expression and OS remains unknown in ovarian cancer. In the present study, we found that the overall survival time of ovarian cancer patients with low EIF2B5 expression was short, while subgroup analysis revealed the same phenomenon with differences in the stage and histologic grade of ovarian cancer. Interestingly, we found that the survival difference was especially significant in older patients. However, this study doesn't contain the variables like race and cancer type, because the races information of TCGA is absent, and only epithelial type exists. Future study needs to explore these variables in other population. Moreover, mesenchymal transition, angiogenesis, coagulation, and bile acid metabolism may be signaling pathways of EIF2B5 in ovarian cancer.
To the best of our knowledge, this is the first study analyzing the prognostic value of the EIF2B5 expression in ovarian cancer. Together with other studies of EIF2B5, our study provides insight into the role of EIF2B5 expression in various cancer types. However, as we did not explore the underlying mechanism of the function of EIF2B in ovarian cancer, future in vitro and in vivo experiments are needed to explore the mechanism in depth.
Conclusion
In the present study, we investigate the predictive value of EIF2B5 expression for ovarian cancer patients' prognosis. We found that low EIF2B5 expression was an independent risk factor for a shorter survival time among ovarian cancer patients. Our future research will include in vitro and in vivo experiments to explore the underlying mechanism of this relationship in depth.
